Essential thrombocythemia (ET) is a neoplastic proliferation of mature myeloid cells - in particular, megakaryocytes - leading to persistently elevated platelet count. Usual clinical presentation is related to an increase in the risk of hemorrhage and/or thrombosis. Management of ET consists of antiplatelet therapies - mainly aspirin and cytoreductive therapies. Coronary involvement in patients...

As “time is brain”, acute ischemic stroke is considered a medical emergency. With the introduction of thrombolytic therapy and availability of modern neuroimaging modalities, timely diagnosis of an ischemic lesion, exclusion of intracerebral hemorrhage, assessing the degree of brain injury, and evaluation of cerebral vasculature is necessary in acute stroke management. Various neuroimaging tech...

BACKGROUND National guidelines have encouraged increased use of thrombolytic therapy for elderly patients with acute myocardial infarction (AMI). However, evidence supporting thrombolytic therapy in patients 75 years and older is lacking. In a retrospective cohort study of 2659 elderly AMI patients, we determined the association between thrombolytic use and in-hospital mortality by age and amon...

0

AIM OF THE STUDY To compare the dynamics of thrombolytic therapy effectiveness in patients with stroke after reorganization medical care using JCI standards. MATERIAL AND METHODS In 2022, a new system for routing at level emergency department was introduced Emergency Care Hospital; and 976 diagnosis brain infarction were treated. The analysis results carried out by comparing mortality rates fro...

Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with a...

In this present series of “Mini-Review: Expert Opinions,” leading clinical investigators present their cases for treatment of acute ST-segment elevation myocardial infarction with thrombolytic therapy or percutaneous coronary intervention (PCI). The investigators review relevant studies and their own experience that support their positions. A review of information provided by Drs Armstrong, Col...

The thrombolytic activity of a novel modified tissue-type plasminogen activator (t-PA) (E6010) was examined in a canine model with copper coil-induced femoral artery thrombus. This model, in which thrombolytic activity can be easily and directly quantified by determining changes in thrombus weight, should be useful for comparing the activities of various thrombolytic agents. Using this model, t...